Viridian reports positive Phase 1/2 data for VRDN-001 in thyroid eye disease; 71% proptosis responders across doses

Viridian Therapeutics, Inc.\DE

3 mg/kg cohort: 67% proptosis responders, 56% overall responders, 67% achieved CAS 0/1, 20% complete diplopia resolution at week 6.
Across all 21 drug-treated patients: 71% proptosis responders, 67% overall responders, 62% CAS 0/1, 54% complete diplopia resolution.
No serious adverse events, discontinuations, or infusion reactions reported with VRDN-001 across dose levels.
Low-dose data support once-monthly subcutaneous dosing profile for VRDN-002 and VRDN-003; VRDN-003 IND planned Q2 2023.
Phase 3 THRIVE trial enrollment ongoing; results expected mid-2024; chronic TED proof-of-concept data expected H1 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.